Payment overview · 2025
General Payments
$614.57
41 reported records · 12 companies
Healthcare provider profile · identity verified
David Michael Whittiker, MD
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA FALLS, TX · NPI 1568462901
Verified facts
What the public records show
CMS Open Payments records show David Michael Whittiker, MD received $614.57 in general payments during 2025 across 41 reported records.
PFIZER INC. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $165.16 | 26.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.16 | 25.2% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.54 | 15.4% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.47 | 6.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.69 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.64 | 4.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.18 | 3.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.49 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.35 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.57 | 2.5% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.98 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.34 | 1.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $594.35 | 40 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $139.12 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $117.25 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.58 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $102.58 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.54 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $94.54 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.58 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.47 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.69 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.64 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.64 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.04 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.04 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.34 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 245 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
208 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
157 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 872 | 241 |
| Levothyroxine Sodium | Levothyroxine Sodium | 752 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 564 | 166 |
| Gabapentin | Gabapentin | 514 | 124 |
| Losartan Potassium | Losartan Potassium | 446 | 122 |
| Lisinopril | Lisinopril | 406 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 397 | 105 |
| Omeprazole | Omeprazole | 320 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 88 |
| Metformin Hcl | Metformin Hcl | 302 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 289 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 270 | 69 |
| Allopurinol | Allopurinol | 259 | 72 |
| Eliquis | Apixaban | 245 | 46 |
| Alprazolam | Alprazolam | 229 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 67 |
| Simvastatin | Simvastatin | 225 | 62 |
| Trulicity | Dulaglutide | 208 | 29 |
| Tramadol Hcl | Tramadol Hcl | 202 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 54 |
| Meloxicam | Meloxicam | 182 | 52 |
| Furosemide | Furosemide | 162 | 56 |
| Ozempic | Semaglutide | 157 | 28 |
| Sertraline Hcl | Sertraline Hcl | 153 | 37 |
| Potassium Chloride | Potassium Chloride | 148 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 42 |
| Montelukast Sodium | Montelukast Sodium | 142 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 37 |
| Finasteride | Finasteride | 132 | 35 |
| Carvedilol | Carvedilol | 127 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 39 |
| Trazodone Hcl | Trazodone Hcl | 116 | 29 |
| Chlorthalidone | Chlorthalidone | 111 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 108 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 100 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 20 |
| Lorazepam | Lorazepam | 96 | 25 |
| Ezetimibe | Ezetimibe | 94 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 89 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 25 |
| Alendronate Sodium | Alendronate Sodium | 86 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 17 |
| Celecoxib | Celecoxib | 82 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 15 |
| Bupropion Xl | Bupropion Hcl | 78 | 25 |
| Spironolactone | Spironolactone | 75 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 13 |
| Mounjaro | Tirzepatide | 68 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 65 | 13 |
| Estradiol | Estradiol | 64 | 23 |
| Donepezil Hcl | Donepezil Hcl | 61 | 16 |
| Glipizide Er | Glipizide | 61 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 11 |
| Temazepam | Temazepam | 58 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 50 | 17 |
| Gemfibrozil | Gemfibrozil | 49 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 17 |
| Buspirone Hcl | Buspirone Hcl | 46 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 13 |
| Baclofen | Baclofen | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 44 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | 12 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 14 |
| Pregabalin | Pregabalin | 40 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | 11 |
| Telmisartan | Telmisartan | 40 | 13 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Nabumetone | Nabumetone | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Famotidine | Famotidine | 37 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 15 |
| Valsartan | Valsartan | 36 | 14 |
| Prednisone | Prednisone | 35 | 23 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 13 |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 11 |
| Topiramate | Topiramate | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nateglinide | Nateglinide | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 12 |
| Cefdinir | Cefdinir | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Fluconazole | Fluconazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $614.57 · 41 records | PFIZER INC. | ABRYSVO, AREXVY, BEXSERO, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, Flector, KRYSTEXXA, Kerendia, Licart, MOUNJARO, NURTEC ODT, Ozempic, PENMENVY, PREVNAR 20, Rybelsus, SHINGRIX, Tirosint, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error